UNSPSC 51363400: Hypnotic ureas

Hypnotic drugs made from a compound formed in the liver from ammonia produced by the deamination of amino acids.

UNSPSC 51363400 Hypnotic ureas is a Class code that nominally names a pharmaceutical ingredient category, but recent state and local solicitations tagged under it actually cover a broader spectrum of pharmaceutical and health-system procurement — from emergency-response medications and drug-deactivation systems to generic pharmaceuticals distributed through cooperative purchasing networks and direct-to-manufacturer prescription programs. State and local governments using this code are acquiring naloxone for community health initiatives, generic multi-source drugs and over-the-counter products through authorized wholesalers, and exploring direct pharmacy-benefit arrangements with manufacturers. Issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple jurisdictions including Oregon).

Recent activity concentrates in Florida, Texas, and the Upper Midwest. Seminole County released an IFB on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries to its Community Health Building, response deadline July 26, 2023. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs for self-insured health plans, with no formal competitive timeline at that stage. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026, and contract effectiveness July 1, 2026. All three opportunities impose compliance requirements including cGMP or FDA certification, insurance coverage, and federal workplace and supply-chain regulations.